Frequency of Hepatitis B Virus infection among Patients before Chemotherapy Treatment

Abstract

Background:Hepatitis B virus (HBV) is an important public health problem worldwide. Chronic HBV in patients undergoing chemotherapy and immunosuppressive treatment are at risk of HBV reactivation. The consequence of HBV reactivation in immunosuppressed patients may lead to liver failure and death. Therefore, this study was conducted to investigate the frequency of HBV markers in cancer patients before chemotherapy. Materials and Methods:In this study cross-sectional, blood samples were collected from 90 cancer patients before chemotherapy. The patient’s sera were tested for the presence of HBsAg and anti-HBc using enzyme-linked immunosorbent assay (ELISA). The HBVDNA was tested for patient’s sera using nested polymerase chain reaction (nested-PCR). Results:Among 90 patients, 42(46.7%) were males and 48 (53.3%) females, with a mean age of 52.52 ± 11.71 years (range, 25–83 years). Of the 6/90 (6.66%) patients, including 4/42 (9.5%) males and 2/48 (4.1%) females cases were positive for HBsAg, anti-HBc and HBV DNA, (P=0.31). The frequency of HBV infection in cancer patients was rectal 3(3.33%), breast cancer 2 (2.22%) and prostate 1(1.11%) cases. The sera of 8/84 (9.52%) patients including 5/39 (12.82%) males and 3/45 (6.66%) females tested positive for anti-HBc, but negative for HBsAg and HBV DNA. (P=0.55). The results of phylogenetic tree revealed that four isolated HBV DNA in cancer patients were cluster with genotype D. Conclusions:High frequency of 6.66% HBV infection have been observed in cancer patients before chemotherapy. The sera of 9.52% patients were only positive for anti-HBc IgG which may indicate the past HBV infection or presence of OBI but requires further investigation. To prevent HBV or OBI reactivation, the screening of HBV DNA and anti HBc should be implemented for cancers patients before chemotherapy.